24 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
The Toronto-Dominion Bank (TD) RBC Capital Markets Canadian Bank CEO Conference (Transcript) https://seekingalpha.com/article/4662017-toronto-dominion-bank-td-rbc-capital-markets-canadian-bank-ceo-conference-transcript?source=feed_sector_transcripts Jan 09, 2024 - The Toronto-Dominion Bank (NYSE:NYSE:TD) RBC Capital Markets Canadian Bank CEO Conference January 9, 2024 1:20 PM ETCompany ParticipantsBharat Masrani -...
TD Bank Group reports unsolicited mini-tender offer by TRC Capital Investment https://seekingalpha.com/news/4054864-td-bank-group-reports-unsolicited-mini-tender-offer-by-trc-capital-investment?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news Jan 12, 2024 - TD Bank Group receives unsolicited mini-tender offer by TRC Capital Investment to purchase 1.5M TD common shares at a 4.3% lower price, which the company...
Telephone and Data Systems, Inc. (TDS) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4671101-telephone-and-data-systems-inc-tds-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Feb 16, 2024 - Telephone and Data Systems, Inc. (NYSE:NYSE:TDS) Q4 2023 Earnings Conference Call February 16, 2024 10:00 AM ETCompany ParticipantsColleen Thompson - VP,...
TD Cowen ups Stoke to buy on updated data for epilepsy drug https://seekingalpha.com/news/4083718-td-cowen-ups-stoke-to-buy-on-updated-data-for-epilepsy-drug?source=feed_sector_healthcare Mar 26, 2024 - TD Cowen upgraded Stoke Therapeutics (STOK) to buy based on updated Phase 1/2 data for the company’s epilepsy drug candidate STK-001. Read more here.
TD Bank: Now Is A Good Time To Buy This 5%-Yielding Blue-Chip Deal https://seekingalpha.com/article/4681247-td-bank-good-time-to-buy-5-percent-yielding-blue-chip-deal?source=feed_all_articles Mar 29, 2024 - TD Bank's financial position is vigorous enough to earn upper investment-grade credit ratings from the three major rating agencies. Read why I rate TD stock a buy.
TD Cowen says sickle cell therapies may get higher CMS payments https://seekingalpha.com/news/4089805-td-cowen-says-sickle-cell-therapies-may-get-higher-cms-payments?source=feed_sector_healthcare Apr 15, 2024 - TD Cowen said recently approved gene therapies by Vertex (VRTX)/CRISPR (CRSP) and bluebird bio (BLUE) may get enhanced payments under proposed CMS guidelines. Read more here.
2 Incredibly Cheap Dividend Stocks to Buy Now https://www.fool.com/investing/2024/04/27/2-incredibly-cheap-dividend-stocks-to-buy-now/?source=iedfolrf0000001 Apr 27, 2024 - These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
3 Incredibly Cheap High-Yield Bank Stocks to Buy Now https://www.fool.com/investing/2024/01/28/3-incredibly-cheap-high-yield-bank-stocks-to-buy/?source=iedfolrf0000001 Jan 28, 2024 - The yields on this trio of Canadian banks are near their highest levels of the past decade. The problems they face aren't that bad.
TD Cowen cuts Immuneering to market perform, cites Phase 1 data https://seekingalpha.com/news/4080047-td-cowen-cuts-immuneering-to-market-perform-cites-phase-1-data?source=feed_sector_healthcare Mar 15, 2024 - TD Cowen has downgraded Immuneering (IMRX) to market perform, citing disappointing data from the company’s Phase 1 study for IMM-1-104 in treating solid tumors. Read more here.
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years https://www.fool.com/investing/2024/05/05/3-super-safe-dividend-stocks-that-have-been-making/?source=iedfolrf0000001 May 05, 2024 - These stocks have rock-solid businesses and they have impressive track records for paying dividends.

Pages: 123

Page 1>